NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 3 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $59,000 | +59.5% | 109,430 | +98.6% | 0.00% | – |
| Q2 2020 | $37,000 | -21.3% | 55,096 | -32.5% | 0.00% | – |
| Q1 2020 | $47,000 | -81.6% | 81,646 | -57.8% | 0.00% | – |
| Q4 2019 | $255,000 | -32.0% | 193,464 | +3.2% | 0.00% | – |
| Q3 2019 | $375,000 | -3.4% | 187,473 | +17.3% | 0.00% | – |
| Q2 2019 | $388,000 | -4.4% | 159,787 | -3.8% | 0.00% | – |
| Q1 2019 | $406,000 | +141.7% | 166,119 | +45.0% | 0.00% | – |
| Q4 2018 | $168,000 | -60.9% | 114,543 | -28.0% | 0.00% | – |
| Q3 2018 | $430,000 | +122.8% | 159,069 | +187.1% | 0.00% | – |
| Q2 2018 | $193,000 | +3116.7% | 55,403 | +4353.6% | 0.00% | – |
| Q1 2018 | $6,000 | -88.7% | 1,244 | -86.1% | 0.00% | – |
| Q4 2017 | $53,000 | +307.7% | 8,932 | +458.2% | 0.00% | – |
| Q3 2017 | $13,000 | -18.8% | 1,600 | +6.7% | 0.00% | – |
| Q2 2017 | $16,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
| Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
| IFP Advisors, Inc | 0 | $0 | 0.00% |